OncoZenge
5,94
SEK
-3,73 %
Mindre end 1K følgere
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-3,73%
-4,81%
+58,4%
+58,4%
-7,04%
+74,71%
-33,18%
-
-51,46%
OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Læs mereMarkedsværdi
69,58 mio. SEK
Aktieomsætning
95,22 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
15.5
2025
Delårsrapport Q1'25
28.5
2025
Generalforsamling '25
21.8
2025
Delårsrapport Q2'25
Alle
Selskabsmeddelelser
ViserAlle indholdstyper
OncoZenge AB receives positive assessment regarding the PCT-patent application for BupiZenge™
OncoZenge AB: OncoZenge enters into SEK 30.2 million investment agreement with new strategic investor Sichuan Yangtian Bio-Pharmaceutical, intended to be carried out through directed share issues
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools